Total Valuation
Pacific Biosciences has a market cap or net worth of €308.58M. The enterprise value is €991.12.
Market Cap€308.58M
Enterprise Value€991.12
Share Statistics
Pacific Biosciences has 310,830,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding310,830,750
Owned by Insiders2.83%
Owned by Institutions23.81%
Financial Efficiency
Pacific Biosciences’s return on equity (ROE) is -102.15 and return on invested capital (ROIC) is -76.32%.
Return on Equity (ROE)-102.15
Return on Assets (ROA)-0.70
Return on Invested Capital (ROIC)-76.32%
Return on Capital Employed (ROCE)-0.76
Revenue Per Employee329.91K
Profits Per Employee-1.13M
Employee Count485
Asset Turnover0.20
Inventory Turnover2.22
Valuation Ratios
The current PE Ratio of Pacific Biosciences is ―. Pacific Biosciences’s PEG ratio is -0.02.
PE Ratio―
PS Ratio3.51
PB Ratio104.87
Price to Fair Value104.87
Price to FCF-4.92
Price to Operating Cash Flow-2.31
PEG Ratio-0.02
Income Statement
In the last 12 months, Pacific Biosciences had revenue of 160.00M and earned -546.38M in profits. Earnings per share was -1.82.
Revenue160.00M
Gross Profit50.67M
Operating Income-557.56M
Pretax Income-546.06M
Net Income-546.38M
EBITDA-34.20M
Earnings Per Share (EPS)-1.82
Cash Flow
In the last 12 months, operating cash flow was -162.74M and capital expenditures -8.42M, giving a free cash flow of -171.16M billion.
Operating Cash Flow-162.74M
Free Cash Flow-171.16M
Free Cash Flow per Share-0.55
Dividends & Yields
Pacific Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.12
52-Week Price Change-11.02%
50-Day Moving Average1.23
200-Day Moving Average1.42
Relative Strength Index (RSI)36.19
Average Volume (3m)475.00
Important Dates
Pacific Biosciences upcoming earnings date is Nov 11, 2026, TBA (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Pacific Biosciences as a current ratio of 6.89, with Debt / Equity ratio of -2126.06%
Current Ratio6.89
Quick Ratio5.99
Debt to Market Cap1.25
Net Debt to EBITDA-20.35
Interest Coverage Ratio-80.18
Taxes
In the past 12 months, Pacific Biosciences has paid 318.00K in taxes.
Income Tax318.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Pacific Biosciences EV to EBITDA ratio is -36.75, with an EV/FCF ratio of -11.03.
EV to Sales7.85
EV to EBITDA-36.75
EV to Free Cash Flow-11.03
EV to Operating Cash Flow-11.30
Balance Sheet
Pacific Biosciences has €236.87M in cash and marketable securities with €706.13M in debt, giving a net cash position of -€469.25M billion.
Cash & Marketable Securities€236.87M
Total Debt€706.13M
Net Cash-€469.25M
Net Cash Per Share-€1.51
Tangible Book Value Per Share-€1.09
Margins
Gross margin is 35.97%, with operating margin of -348.46%, and net profit margin of -341.47%.
Gross Margin35.97%
Operating Margin-348.46%
Pretax Margin-341.28%
Net Profit Margin-341.47%
EBITDA Margin-21.37%
EBIT Margin-336.93%
Analyst Forecast
The average price target for Pacific Biosciences is €2.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€2.30
Price Target Upside98.45% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-4.85%
EPS Growth Forecast77.95%